CLS001 (Omiganan) — Competitive Intelligence Brief

CLS001 (Omiganan) (CLS001 (Omiganan)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial peptide. Area: Infectious Disease / Dermatology.

phase 3 Antimicrobial peptide Bacterial cell membrane (lipopolysaccharides and lipoteichoic acids) Infectious Disease / Dermatology Small molecule

Target snapshot

CLS001 (Omiganan) (CLS001 (Omiganan)) — Maruho Co., Ltd.. Omiganan is an antimicrobial peptide that disrupts bacterial cell membranes by binding to lipopolysaccharides and lipoteichoic acids, leading to bacterial cell death.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CLS001 (Omiganan) TARGET	CLS001 (Omiganan)	Maruho Co., Ltd.	phase 3	Antimicrobial peptide	Bacterial cell membrane (lipopolysaccharides and lipoteichoic acids)
PNA	PNA	Guangzhou Yipinhong Pharmaceutical CO.,LTD	marketed	Antimicrobial peptide	Bacterial cell membranes
Topical pexiganan cream 0.8%	Topical pexiganan cream 0.8%	Dipexium Pharmaceuticals, Inc.	phase 3	Antimicrobial peptide	Bacterial cell membrane
MSI-78	MSI-78	Abeona Therapeutics, Inc	phase 3	Antimicrobial peptide	Bacterial cell membrane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial peptide class)

1. Abeona Therapeutics, Inc · 1 drug in this class
2. Dipexium Pharmaceuticals, Inc. · 1 drug in this class
3. Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 drug in this class
4. Maruho Co., Ltd. · 1 drug in this class
5. Tufts Medical Center · 1 drug in this class